Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent

Blood Reviews

Volumn 29, Issue 3, 2015, Pages 179-189

  French, Shauna L ^a,b   Arthur, Jane F ^a,b   Tran, Huyen A ^a,b   Hamilton, Justin R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antiplatelet agents; Arterial thrombosis; Platelets; Protease activated receptors; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATOPAXAR; CLOPIDOGREL; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR; RIVAROXABAN; THROMBIN; THROMBIN RECEPTOR; TICAGRELOR; VORAPAXAR; LACTONE; PROTEINASE ACTIVATED RECEPTOR 1; PYRIDINE DERIVATIVE;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HUMAN; LIMB ISCHEMIA; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FOOD AND DRUG ADMINISTRATION; METABOLISM; MOLECULARLY TARGETED THERAPY; THROMBOCYTE; UNITED STATES;

BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; LACTONES; MOLECULAR TARGETED THERAPY; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84929504686     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.10.006     Document Type: Article

References (102)

1. Alwan A. Global status report on noncommunicable diseases 2010 2011, World Health Organization.
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329):71-86. Trialists' Collaboration A.
3. Hamm C.W., Bassand J.-P., Agewall S., Bax J., Boersma E., Bueno H., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32(23):2999-3054.
4. Savage B., Almus-Jacobs F., Ruggeri Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998, 94(5):657-666.
5. Vicente V., Kostel P., Ruggeri Z. Isolation and functional characterization of the von Willebrand factor-binding domain located between residues His1-Arg293 of the alpha-chain of glycoprotein Ib. J Biol Chem 1988, 263(34):18473-18479.
6. White J.G. Platelet structure. Platelets 2013, 117-145. Academic Press, London. Third ed. A.D. Michelson (Ed.).
7. Scarborough R.M., Kleiman N.S., Phillips D.R. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use?. Circulation 1999, 100(4):437-444.
8. Kastrati A., Mehilli J., Neumann F.-J., Dotzer F., ten Berg J., Bollwein H., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006, 295(13):1531-1538.
9. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107(23):2908-2913.
10. Goodman T., Ferro A., Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008, 66(2):222-232.
11. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41(6):961-965.
12. Järemo P., Lindahl T., Fransson S.G., Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002, 252(3):233-238.
13. Committee C.S. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348(9038):1329-1339.
14. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354(16):1706-1717.
15. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407(6801):258-264.
16. Kahn M.L., Zheng Y.-W., Huang W., Bigornia V., Zeng D., Moff S., et al. A dual thrombin receptor system for platelet activation. Nature 1998, 394(6694):690-694.
17. Vu T.-K.H., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64(6):1057-1068.
18. Xu W.-f., Andersen H., Whitmore T.E., Presnell S.R., Yee D.P., Ching A., et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci 1998, 95(12):6642-6646.
19. Ishihara H., Connolly A.J., Zeng D., Kahn M.L., Zheng Y.W., Timmons C., et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997, 386:502-506.
20. Howells G.L., Macey M.G., Chinni C., Hou L., Fox M.T., Harriott P., et al. Proteinase-activated receptor-2: expression by human neutrophils. J Cell Sci 1997, 110(7):881-887.
21. Bono F., Lamarche I., Herbert J. Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2). Biochem Biophys Res Commun 1997, 241(3):762-764.
22. Molino M., Woolkalis M.J., Reavey-Cantwell J., Praticó D., Andrade-Gordon P., Barnathan E.S., et al. Endothelial cell thrombin receptors and PAR-2 - two protease-activated receptors located in a single cellular environment. J Biol Chem 1997, 272(17):11133-11141.
23. Hamilton J.R., Chow J.M., Cocks T.M. Protease-activated receptor-2 turnover stimulated independently of receptor activation in porcine coronary endothelial cells. Br J Pharmacol 1999, 127(3):617-622.
24. Glembotski C.C., Irons C., Krown K., Murray S., Sprenkle A., Sei C. Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J Biol Chem 1993, 268(27):20646-20652.
25. Sabri A., Muske G., Zhang H., Pak E., Darrow A., Andrade-Gordon P., et al. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res 2000, 86(10):1054-1061.
26. Sabri A., Short J., Guo J., Steinberg S.F. Protease-activated receptor-1 mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ Res 2002, 91(6):532-539.
27. Nystedt S., Emilsson K., Larsson A.K., Strömbeck B., Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem 1995, 232(1):84-89.
28. Molino M., Barnathan E.S., Numerof R., Clark J., Dreyer M., Cumashi A., et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997, 272(7):4043-4049.
29. Camerer E., Huang W., Coughlin S.R. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci 2000, 97(10):5255-5260.
30. Takeuchi T., Harris J.L., Huang W., Yan K.W., Coughlin S.R., Craik C.S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000, 275(34):26333-26342.
31. Wilson S., Greer B., Hooper J., Zijlstra A., Walker B., Quigley J., et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005, 388:967-972.
32. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999, 103(6):879-887.
33. Sims P., Wiedmer T., Esmon C.T., Weiss H., Shattil S. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989, 264(29):17049-17057.
34. Covic L., Gresser A.L., Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000, 39(18):5458-5467.
35. Scarborough R., Naughton M., Teng W., Hung D., Rose J., Vu T., et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem 1992, 267(19):13146-13149.
36. Hung D., Wong Y., Vu T.-K., Coughlin S. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem 1992, 267(29):20831-20834.
37. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006, 99(12):1293-1304.
38. Klages B., Brandt U., Simon M.I., Schultz G., Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999, 144(4):745-754.
39. Offermanns S., Toombs C.F., Hu Y.-H., Simon M.I. Defective platelet activation in Gαq-deficient mice. Nature 1997, 389(6647):183-186.
40. Liu L.-W., Vu T., Esmon C., Coughlin S. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem 1991, 266(26):16977-16980.
41. Nieman M.T., Schmaier A.H. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry 2007, 46(29):8603-8610.
42. Jacques S.L., LeMasurier M., Sheridan P.J., Seeley S.K., Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor - enhancement of macromolecular association and cleavage. J Biol Chem 2000, 275(52):40671-40678.
43. Covic L., Singh C., Smith H., Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost 2002, 87(4):722-727.
44. Jacques S., Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem J 2003, 376:733-740.
45. Sambrano G.R., Weiss E.J., Zheng Y.-W., Huang W., Coughlin S.R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001, 413(6851):74-78.
46. Hollenberg M.D., Saifeddine M., Al-Ani B. Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides. Mol Pharmacol 1996, 49:229-233.
47. Khan T.A., Bianchi C., Voisine P., Sandmeyer J., Feng J., Sellke F.W. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thorac Surg 2005, 79(5):1545-1550.
48. Andrade-Gordon P., Maryanoff B.E., Derian C.K., Zhang H.C., Addo M.F., Darrow A.L., et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A 1999, 96(22):12257-12262.
49. Weiss E.J., Hamilton J.R., Lease K.E., Coughlin S.R. Protection against thrombosis in mice lacking PAR3. Blood 2002, 100(9):3240-3244.
50. Nakanishi-Matsui M., Zheng Y.W., Sulciner D.J., Weiss E.J., Ludeman M.J., Coughlin S.R. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000, 404(6778):609-613.
51. Hamilton J., Cornelissen I., Coughlin S. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004, 2(8):1429-1435.
52. Lee H., Sturgeon S., Mountford J., Jackson S., Hamilton J. Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Br J Pharmacol 2012, 166(7):2188-2197.
53. Vandendries E.R., Hamilton J.R., Coughlin S.R., Furie B., Furie B.C. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A 2007, 104(1):288-292.
54. Andrade-Gordon P., Derian C.K., Maryanoff B.E., Zhang H.C., Addo M.F., Cheung W., et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 2001, 298(1):34-42.
55. Hollenberg M.D., Saifeddine M., Sandhu S., Houle S., Vergnolle N. Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br J Pharmacol 2004, 143(4):443-454.
56. Kuliopulos A., Covic L. Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis. Life Sci 2003, 74(2):255-262.
57. Cook J.J., Sitko G.R., Bednar B., Condra C., Mellott M.J., Feng D.-M., et al. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 1995, 91(12):2961-2971.
58. Derian C.K., Damiano B.P., Addo M.F., Darrow A.L., D'Andrea M.R., Nedelman M., et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003, 304(2):855-861.
59. Matsuoka T., Kogushi M., Kawata T., Kimura A., Chiba K.-i., Musha T., et al. 1102-48 Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J Am Coll Cardiol 2004, 43(5):A68.
60. Kogushi M., Matsuoka T., Kawata T., Kuramochi H., Kawaguchi S., Murakami K., et al. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol 2011, 657(1):131-137.
61. Kai Y., Hirano K., Maeda Y., Nishimura J., Sasaki T., Kanaide H. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke 2007, 38(12):3259-3265.
62. Wiviott S.D., Flather M.D., O'Donoghue M.L., Goto S., Fitzgerald D.J., Cura F., et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease Trial. Circulation 2011, 123(17):1854-1863.
63. O'Donoghue M.L., Bhatt D.L., Wiviott S.D., Goodman S.G., Fitzgerald D.J., Angiolillo D.J., et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 2011, 123(17):1843-1853.
64. Goto S., Ogawa H., Takeuchi M., Flather M.D., Bhatt D.L. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010, 31(21):2601-2613.
65. Kosoglou T., Reyderman L., Tiessen R.G., van Vliet A.A., Fales R.R., Keller R., et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol 2012, 68(3):249-258.
66. Becker R.C., Moliterno D.J., Jennings L.K., Pieper K.S., Pei J., Niederman A., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009, 373(9667):919-928.
67. Ghosal A., Lu X., Penner N., Gao L., Ramanathan R., Chowdhury S.K., et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos 2011, 39(1):30-38.
68. Morrow D.A., Braunwald E., Bonaca M.P., Ameriso S.F., Dalby A.J., Fish M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012, 366(15):1404-1413.
69. Tricoci P., Huang Z., Held C., Moliterno D.J., Armstrong P.W., Van de Werf F., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012, 366(1):20-33.
70. Leonardi S., Tricoci P., White H.D., Armstrong P.W., Huang Z., Wallentin L., et al. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Eur Heart J 2013, 34:1723-1731.
71. Capodanno D., Bhatt D., Goto S., O'Donoghue M., Moliterno D., Tamburino C., et al. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost 2012, 10(10):2006-2015.
72. Whellan D.J., Tricoci P., Chen E., Huang Z., Leibowitz D., Vranckx P., et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol 2014, 63(11):1048-1057.
73. Duerschmied D., Bode C. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?. Hamostaseologie 2011, 32(3):221-227.
74. Scirica B.M., Bonaca M.P., Braunwald E., De Ferrari G.M., Isaza D., Lewis B.S., et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P-TIMI 50 trial. Lancet 2012, 380(9850):1317-1324.
75. Bonaca M.P., Scirica B.M., Creager M.A., Olin J., Bounameaux H., Dellborg M., et al. Vorapaxar in patients with peripheral artery disease results from TRA2° P-TIMI 50. Circulation 2013, 127(14):1522-1529.
76. Morrow D.A., Alberts M.J., Mohr J.P., Ameriso S.F., Bonaca M.P., Goto S., et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 2013, 44(3):691-698.
77. Merlini P.A., Bauer K.A., Oltrona L., Ardissino D., Cattaneo M., Belli C., et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994, 90(1):61-68.
78. Szczeklik A., Dropinski J., Radwan J., Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb Vasc Biol 1992, 12(5):548-553.
79. Huisse M.-G., Lanoy E., Tcheche D., Feldman L.J., Bezeaud A., Anglès-Cano E., et al. Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. Thromb Haemost 2007, 98(2):420.
80. Inauen W., Baumgartner H.R., Bombeli T., Haeberli A., Straub P.W. Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood. Arteriosclerosis 1990, 10(4):607-615.
81. Kirchhofer D., Sakariassen K.S., Clozel M., Tschopp T.B., Hadvary P., Nemerson Y., et al. Relationship between tissue factor expression and deposition of fibrin, platelets, and leukocytes on cultured endothelial cells under venous blood flow conditions. Blood 1993, 81(8):2050-2058.
82. Fressinaud E., Sakariassen K.S., Rothschild C., Baumgartner H.R., Meyer D. Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A. Blood 1992, 80(4):988-994.
83. Lee H., Sturgeon S.A., Jackson S.P., Hamilton J.R. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions. Thromb Haemost 2012, 107(2):328.
84. Berny M.A., Munnix I.C., Auger J.M., Schols S.E., Cosemans J.M., Panizzi P., et al. Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One 2011, 5(4):e10415.
85. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007, 50(19):1822-1834.
86. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005, 46(10):1820-1826.
87. Mahaffey K.W., Huang Z., Wallentin L., Storey R.F., Jennings L.K., Tricoci P., et al. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol 2014, 113(6):936-944.
88. Cornelissen I., Palmer D., David T., Wilsbacher L., Concengco C., Conley P., et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc Natl Acad Sci 2010, 107(43):18605-18610.
89. Kreutz R.P., Breall J.A., Kreutz Y., Owens J., Lu D., Bolad I., et al. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response. Thromb Res 2012, 130(2):198-202.
90. Askie L.M., Duley L., Henderson-Smart D.J., Stewart L.A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007, 369(9575):1791-1798.
91. Bates S.M., Greer I.A., Hirsh J., Ginsberg J.S. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(Suppl. 3):627S-644S.
92. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20):2001-2015.
93. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-1057.
94. Mega J.L., Braunwald E., Wiviott S.D., Bassand J.-P., Bhatt D.L., Bode C., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366(1):9-19.
95. Italiano J.E., Richardson J.L., Patel-Hett S., Battinelli E., Zaslavsky A., Short S., et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111(3):1227-1233.
96. Duvernay M., Young S., Gailani D., Schoenecker J., Hamm H.E. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Mol Pharmacol 2013, 83(4):781-792.
97. Covic L., Misra M., Badar J., Singh C., Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002, 8:1161-1165.
98. Mumaw M., la Fuente M., Noble D., Nieman M. Targeting the anionic region of human protease activated receptor 4 (PAR4) inhibits platelet aggregation and thrombosis without interfering with hemostasis. J Thromb Haemost 2014, 12:1-11.
99. Wu C.C., Huang S.W., Hwang T.L., Kuo S.C., Lee F.Y., Teng C.M. YD-3, a novel inhibitor of protease-induced platelet activation. Br J Pharmacol 2000, 130(6):1289-1296.
100. Lee H., Hamilton J.R. Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. Pharmacol Ther 2012, 134(2):246-259.
101. Judge H.M., Jennings L.K., Moliterno D.J., Hord E., Ecob R., Tricoci P., et al. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. Platelets 2014, 0:1-7.
102. Arachiche A., de la Fuente M., Nieman M.T. Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets. PLoS One 2014, 9(5):e97724.